晚期膀胱癌PD-1/PD-L1抑制剂治疗的研究进展

摘要
图/表
参考文献(29)
相关文章 (5)

全文: PDF (619 KB) HTML (1 KB)
输出: BibTeX | EndNote (RIS)

摘要膀胱癌作为泌尿系统常见肿瘤，目前常见的治疗方法包括手术治疗和化疗，然而对于晚期膀胱癌患者的疗效仍不尽如人意。近年来，随着以程序性细胞死亡分子1（PD-1）/程序性细胞死亡分子配体1（PD-L1）抑制剂等免疫检查点抑制剂为代表的免疫治疗的出现，使晚期膀胱癌的治疗出现了新的希望。PD-1/PD-L1抑制剂可以阻断PD-1/PD-L1结合，从而阻断负性免疫调节信号，进而提高抗肿瘤免疫活性。本文将通过分析临床试验研究的数据和结果对PD-1/PD-L1抑制剂在晚期膀胱癌治疗中的作用机制、现况及不良反应等进行综述，为晚期膀胱癌患者的临床治疗提供帮助。

	服务

	把本文推荐给朋友
	加入我的书架
	加入引用管理器
	E-mail Alert
	RSS
	作者相关文章
	李彦泽王磊陈志远刘修恒

关键词 ：晚期膀胱癌, 程序性细胞死亡分子1/程序性细胞死亡分子配体1抑制剂, 免疫检查点抑制剂, 免疫治疗

Abstract：Bladder cancer is a common cancer in the urinary system. The current common treatments include surgery and chemotherapy. However, the efficacy of patients with advanced bladder cancer is still unsatisfactory. In recent years, with the advent of immunotherapy represented by immunological checkpoint inhibitors such as programmed cell death 1 (PD-1)/programmed cell death ligation 1 (PD-L1) inhibitors, new treatments for advanced bladder cancer have emerged. PD-1/PD-L1 inhibitors block PD-1/PD-L1 binding, thereby blocking negative immune regulatory signals, then enhancing anti-tumor immune activity. This article will review the principles, current status and adverse effects of PD-1/PD-L1 inhibitors in the treatment of advanced bladder cancer through analyzing data and results in clinical trials, and provide assistance for the clinical treatment of patients with advanced bladder cancer.

Key words： Advanced bladder cancer Programmed cell death 1/programmed cell death ligation 1 inhibitor Immunological checkpoint inhibitor Immunotherapy

基金资助:湖北省知识创新专项（自然科学基金）项目（2017CFB181）；
湖北省武汉市青年科技晨光计划项目（2017050304010281）。

通讯作者: 刘修恒（1962.9-），男，医学博士，教授，主任医师，博士研究生导师；研究方向：泌尿系统结石、肿瘤、前列腺疾病的诊断及治疗。

作者简介: 李彦泽（1994.10-），男，武汉大学第一临床学院2017级外科学（泌尿外科方向）专业在读硕士研究生；研究方向：泌尿系肿瘤免疫治疗。

引用本文:

李彦泽王磊陈志远刘修恒. 晚期膀胱癌PD-1/PD-L1抑制剂治疗的研究进展[J]. 中国医药导报, 2020, 17(4): 40-43,51.
LI Yanze WANG Lei CHEN Zhiyuan LIU Xiuheng. Research progress of PD-1/PD-L1 inhibitors for the treatment of advanced bladder cancer. 中国医药导报, 2020, 17(4): 40-43,51.

链接本文:

http://www.yiyaodaobao.com.cn/CN/ 或 http://www.yiyaodaobao.com.cn/CN/Y2020/V17/I4/40

[1] Chen W，Zheng R，Baade PD，et al. Cancer statistics in China，2015 [J]. CA Cancer J Clin，2016，66（2）：115-132.
[2] Kim J. Immune checkpoint blockade therapy for bladder cancer treatment [J]. Investig Clin Urol，2016，57（Suppl 1）：S98-S105.
[3] Postow MA，Callahan MK，Wolchok JD. Immune checkpoint blockade in cancer therapy [J]. J Clin Oncol，2015，33（17）：1974-1982.
[4] Siefker-Radtke AO，Apolo AB，Bivalacqua TJ，et al. Immunotherapy with checkpoint blockade in the treatment of urothelial carcinoma [J]. J Urol，2018，199（5）：1129-1142.
[5] Sundararajan S，Vogelzang NJ. Anti-PD-1 and PD-L1 therapy for bladder cancer：what is on the horizon? [J]. Future Oncol，2015，11（16）：2299-2306.
[6] Koshkin VS，Grivas P. Emerging role of immunotherapy in advanced urothelial carcinoma [J]. Curr Oncol Rep，2018， 20（6）：48.
[7] Ning YM，Suzman D，Maher VE，et al. FDA approval summary：Atezolizumab for the treatment of patients with progressive advanced urothelial carcinoma after platinum-containing chemotherapy [J]. Oncologist，2017，22（6）：743-749.
[8] Herbst RS，Soria JC，Kowanetz M，et al. Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients [J]. Nature，2014，515（7528）：563-567.
[9] Petrylak D，Powles T，Bellmunt J，et al. Atezolizumab（atezo）in patients with metastatic urothelial carcinoma（mUC）：a 2-year clinical update from a phase Ⅰa study [J]. J Clin Oncol，2017，35（6 Suppl）：290.
[10] Rosenberg JE，Hoffman-censits J，Powles T，et al. Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy：a single-arm， multicentre，phase 2 trial [J]. Lancet，2016，387（10031）：1909-1920.
[11] Powles T，Durán I，van der Heijden MS，et al. Atezolizumab versus chemotherapy in patients with platinum-treated locally advanced or metastatic urothelial carcinoma（IMvigor211）：a multicentre，open-label，phase 3 randomised controlled trial [J]. Lancet，2017，S0140673 61733297X：1-11.
[12] Brahmer JR，Hammers H，Lipson EJ. Nivolumab：targeting PD-1 to bolster antitumor immunity [J]. Future Oncol，2015，11（9）：1307-1326.
[13] Sharma P，Callahan MK，Bono P，et al. Nivolumab monotherapy in recurrent metastatic urothelial carcinoma （CheckMate 032）：a multicentre，open-label，two-stage，multi-arm，phase 1/2 trial [J]. Lancet Oncol，2016，17（11）：1590-1598.
[14] Sharma P，Retz M，Siefker-radtke A，et al. Nivolumab in metastatic urothelial carcinoma after platinum therapy （CheckMate 275）：a multicentre，singlearm，phase 2 trial [J]. Lancet Oncol，2017，18（3）：312-322.
[15] Raggi D，Miceli R，Sonpavde G，et al. Second-line single-agent versus doublet chemotherapy as salvage therapy for metastatic urothelial cancer：a systematic review and meta-analysis [J]. Ann Oncol，2016，27（1）：49-61.
[16] Massard C，Gordon MS，Sharma S，et al. Safety and efficacy of Durvalumab（MEDI4736），an anti-programmed cell death Ligand-1 immune checkpoint inhibitor，in patients with advanced Urothelial bladder cancer [J]. J Clin Oncol，2016，34（26）：3119-3125.
[17] Hahn NM，Powles T，Massard C，et al. Updated efficacy and tolerability of durvalumab in locally advanced or metastatic urothelial carcinoma（UC）[J]. J Clin Oncol，2017，35（15 Suppl）：4525.
[18] Powles T，O′donnell PH，Massard C，et al. Efficacy and safety of durvalumab in locally advanced or metastatic urothelial carcinoma：updated results from a phase 1/2 open-label study [J]. JAMA Oncol，2017，3（9）：e172411.
[19] Powles T，O′donnell PH，Massard C，et al. Updated efficacy and tolerability of durvalumab in locally advanced and metastatic urothelial carcinoma [J]. J Clin Oncol，2017， 35（6 Suppl）：286.
[20] Heery CR，O′sullivan coyne GH，Madan RA，et al. Phase Ⅰ open-label，multiple ascending dose trial of MSB0010 718C，an anti-PD-L1 monoclonal antibody in advanced solid malignancies [J]. J Clin Oncol，2014，32（15 Suppl）：3064.
[21] Boyerinas B，Jochems C，Fantini M，et al. Antibody-dependent cellular cytotoxicity activity of a novel anti-PD-L1 antibody avelumab（MSB0010718C）on human tumor cells [J]. Cancer Immunol Res，2015，3（10）：1148-1157.
[22] Grenga I，Donahue RN，Lepone LM，et al. A fully human IgG1 anti-PD-L1 MAb in an in vitro assay enhances antigen-specific T-cell responses [J]. Clin Transl Immunol，2016，5（5）：e83.1-e83.12.
[23] Heery CR，O′sullivan-coyne G，Madan RA，et al. Avelumab for metastatic or locally advanced previously treated solid tumors（JAVELIN Solid Tumor）：a phase 1a，multicohort，dose-escalation trial [J]. Lancet Oncol，2017，18（5）：587-598.
[24] Apolo AB，Infante JR，Balmanoukian A，et al. Avelumab，an anti-programmed death-ligand 1 antibody，in patients with refractory metastatic urothelial carcinoma：results from a multicenter，phase Ⅰb study [J]. J Clin Oncol，2017，35（19）：2117-2124.
[25] Khoja L，Butler MO，Kang SP，et al. Pembrolizumab [J]. J Immuno Ther Cancer，2015，3（1）：36.
[26] Bellmunt J，De wit R，Vaughn DJ，et al. KEYNOTE-045 investigators. Pembrolizumab as second-line therapy for advanced urothelial carcinoma [J]. New Engl J Med，2017，376（11）：1015-1026.
[27] Michot JM，Bigenwald C，Champiat S，et al. Immune-related adverse events with immune checkpoint blockade：a comprehensive review [J]. Eur J Cancer，2016，54：139-148.
[28] Weber JS，Kahler KC，Hauschild A. Management of immune-related adverse events and kinetics of response with ipilimumab [J]. J Clin Oncol，2012，30（21）：2691-2697.
[29] Champiat S，Lambotte O，Barreau E，et al. Management of immune checkpoint blockade dysimmune toxicities：a collaborative position paper [J]. Ann Oncol，2015，27（4）：559-574.